{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:16:26Z","timestamp":1791908186577,"version":"4.3.4"},"reference-count":122,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Acromegaly is a chronic endocrine disorder characterized by excessive secretion of growth hormone (GH), predominantly caused by pituitary adenomas. Despite advancements in neurosurgical techniques, the surgical remission rates for invasive macroadenomas or giant adenomas remain unsatisfactory. Therefore, multimodal treatment strategies, including preoperative medical therapy (POMT), have been implemented to improve patient outcomes. Among these, first-generation somatostatin receptor ligands (fg-SRLs) have been the most extensively studied preoperative agents; however, their clinical efficacy in enhancing postoperative remission remains controversial. In recent decades, ongoing research into novel drugs and molecular targets are reshaping the therapeutic landscape of POMT. Beyond traditional clinical models and functional assays, the integration of advanced imaging modalities and molecular biomarkers promises to refine patient stratification, particularly for individuals with suboptimal responses to transsphenoidal surgery (TSS). Furthermore, novel SRL formulations and the identification of new molecular targets could further expand the therapeutic landscape of POMT. In this narrative review, we systematically summarize the latest research advancements in POMT for acromegaly and discusses potential therapeutic strategies and persisting obstacles in this field.<\/jats:p>","DOI":"10.3389\/fendo.2025.1636047","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T05:24:47Z","timestamp":1767331487000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Preoperative medical therapy for acromegaly: current knowledge and clinical significance"],"prefix":"10.3389","volume":"16","author":[{"given":"Dan","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.12.7042","article-title":"Ten-year follow-up results of transsphenoidal microsurgery in acromegaly","volume":"85","author":"Biermasz","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2012.04492.x","article-title":"Outcome of multimodal therapy in operated acromegalic patients, a study in 115 patients","volume":"78","author":"Albarel","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0554","article-title":"Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome","volume":"96","author":"Jane","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3171\/2019.6.Jns191187","article-title":"Long-term outcomes of transsphenoidal surgery for management of growth hormone-secreting adenomas: single-center results","volume":"133","author":"Asha","year":"2020","journal-title":"J Neurosurg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2020.12.013","article-title":"Prognostic factors of acromegalic patients with growth hormone-secreting pituitary adenoma after transsphenoidal surgery","volume":"146","author":"Taweesomboonyat","year":"2021","journal-title":"World Neurosurg"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01296-4","article-title":"Predictive model of surgical remission in acromegaly: age, presurgical gh levels and knosp grade as the best predictors of surgical remission","volume":"44","author":"Araujo-Castro","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad568","article-title":"New treatments for acromegaly in development","volume":"109","author":"Gadelha","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvae045","article-title":"Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: remah study","volume":"190","author":"Sampedro-Nu\u00f1ez","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s0026-0495(96)90088-8","article-title":"Presurgical octreotide: treatment in acromegaly","volume":"45","author":"Stevenaert","year":"1996","journal-title":"Metabolism"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2004.02045.x","article-title":"One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide autogel","volume":"60","author":"Caron","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2165\/11318510-000000000-00000","article-title":"Medical therapy of acromegaly: efficacy and safety of somatostatin analogues","volume":"69","author":"Feelders","year":"2009","journal-title":"Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/cen.14790","article-title":"Preoperative medical treatments and surgical approaches for acromegaly: A systematic review","volume":"98","author":"Papaioannou","year":"2023","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-025-01134-8","article-title":"Pituitary incidentaloma: A pituitary society international consensus guideline statement","volume":"21","author":"Fleseriu","year":"2025","journal-title":"Nat Rev Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-024-00993-x","article-title":"Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management","volume":"20","author":"Esposito","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s11154-024-09875-z","article-title":"The changing landscape of acromegaly - an epidemiological perspective","volume":"25","author":"Rosendal","year":"2024","journal-title":"Rev Endocr Metab Disord"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-67-5-1040","article-title":"Preoperative treatment of acromegaly with long-acting somatostatin analog sms 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate","volume":"67","author":"Barkan","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.145.6.1131","article-title":"Ct of the sella turcica after transsphenoidal resection of pituitary adenomas","volume":"145","author":"Kaplan","year":"1985","journal-title":"AJR Am J Roentgenol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1210\/jcem-60-4-698","article-title":"Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study","volume":"60","author":"Molitch","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2021.11.007","article-title":"Diagnosis and treatment of acromegaly: an update","volume":"97","author":"Ershadinia","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(22)00244-3","article-title":"Acromegaly: pathogenesis, diagnosis, and management","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nrendo.2011.42","article-title":"Medical therapy in acromegaly","volume":"7","author":"Sherlock","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00514-0","article-title":"Drug resistance in pituitary tumours: from cell membrane to intracellular signalling","volume":"17","author":"Peverelli","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.17.9343","article-title":"Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5","volume":"94","author":"Cordelier","year":"1997","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.01191","article-title":"Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2","volume":"13","author":"Ferrante","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1172\/jci19933","article-title":"Central and peripheral actions of somatostatin on the growth hormone-igf-I axis","volume":"114","author":"Murray","year":"2004","journal-title":"J Clin Invest"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1530\/erc-16-0151","article-title":"Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future","volume":"23","author":"\u00d6berg","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21051682","article-title":"Somatostatin analogs in clinical practice: A review","volume":"21","author":"Gomes-Porras","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000381460","article-title":"Pasireotide in acromegaly: an overview of current mechanistic and clinical data","volume":"102","author":"Samson","year":"2015","journal-title":"Neuroendocrinology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02275-1","article-title":"Real-life data of pasireotide lar in acromegaly: A long-term follow-up","volume":"47","author":"Urbani","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-022-09710-3","article-title":"Pasireotide-a Novel Somatostatin Receptor Ligand after 20 years of Use","volume":"23","author":"Bolanowski","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00931","article-title":"Evaluation of the efficacy and safety of switching to pasireotide in patients with acromegaly inadequately controlled with first-generation somatostatin analogs","volume":"10","author":"Gadelha","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2016.02.003","article-title":"Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for na\u00efve active acromegaly","volume":"115","author":"Chang","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ17-0487","article-title":"Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly","volume":"65","author":"Yamamoto","year":"2018","journal-title":"Endocr J"},{"key":"B35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1530\/eje-08-0910","article-title":"Pituitary tumor size in acromegaly during pegvisomant treatment: experience from mr re-evaluations of the german pegvisomant observational study","volume":"161","author":"Buchfelder","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1239","article-title":"Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: A prospective multicenter study","volume":"95","author":"Buhk","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1530\/eje-08-0205","article-title":"Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials","volume":"159","author":"Jimenez","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1530\/eje.1.02312","article-title":"Treatment of acromegaly with the gh receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the german pegvisomant observational study","volume":"156","author":"Schreiber","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02281","article-title":"Pegvisomant improves glucose metabolism in acromegaly: A meta-analysis of prospective interventional studies","volume":"104","author":"Feola","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1530\/eje-21-0239","article-title":"More than a decade of real-world experience of pegvisomant for acromegaly: acrostudy","volume":"185","author":"Fleseriu","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz116","article-title":"Obstructive sleep apnea in acromegaly and the effect of treatment: A systematic review and meta-analysis","volume":"105","author":"Parolin","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1530\/eje-12-0596","article-title":"Treatment with gh receptor antagonist in acromegaly: effect on cardiac arrhythmias","volume":"168","author":"Auriemma","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"30","DOI":"10.17925\/ee.2019.15.1.30","article-title":"Functioning pituitary adenomas - current treatment options and emerging medical therapies","volume":"15","author":"Varlamov","year":"2019","journal-title":"Eur Endocrinol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1347253","article-title":"Novel use of endogenous gh-measurement directly after transsphenoidal microsurgery in acromegaly treated with pegvisomant","volume":"121","author":"L\u00fcdecke","year":"2013","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1385\/endo:14:3:329","article-title":"Dopamine D2 receptor gene expression in human adenohypophysial adenomas","volume":"14","author":"Stefaneanu","year":"2001","journal-title":"Endocrine"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1530\/eje-08-0306","article-title":"Clinical use of cabergoline as primary and adjunctive treatment for acromegaly","volume":"159","author":"Moyes","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1023\/b:pitu.0000044630.83354.f0","article-title":"Cabergoline therapy of growth hormone & Growth hormone\/prolactin secreting pituitary tumors","volume":"7","author":"Freda","year":"2004","journal-title":"Pituitary"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.k10e-203","article-title":"Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: A prospective randomized study","volume":"57","author":"Shen","year":"2010","journal-title":"Endocr J"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1450137","article-title":"Effects of preoperative octreotide treatment on different subtypes of 90 gh-secreting pituitary adenomas and outcome in one surgical centre","volume":"145","author":"Abe","year":"2001","journal-title":"Eur J Endocrinol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.53.125","article-title":"Short-term preoperative octreotide treatment of gh-secreting pituitary adenoma: predictors of tumor shrinkage","volume":"53","author":"Oshino","year":"2006","journal-title":"Endocr J"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1530\/eje-09-0908","article-title":"Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: A prospective, randomised trial","volume":"162","author":"Mao","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-005-0511-9","article-title":"Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (Gh) concentration and pituitary function. A long-term case-control study","volume":"147","author":"Pl\u00f6ckinger","year":"2005","journal-title":"Acta Neurochir (Wien)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.03982.x","article-title":"Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure","volume":"74","author":"Carlsen","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0677-y","article-title":"The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly","volume":"19","author":"Colao","year":"2016","journal-title":"Pituitary"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa424","article-title":"Normal insulin-like growth factor 1 during somatostatin receptor ligand treatment predicts surgical cure in acromegaly","volume":"105","author":"Losa","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.82.10.4283","article-title":"Effect of octreotide pretreatment on surgical outcome in acromegaly","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0315","article-title":"Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: A prospective, randomized trial","volume":"93","author":"Carlsen","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B59","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3171\/jns.2006.104.6.899","article-title":"Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates","volume":"104","author":"Losa","year":"2006","journal-title":"J Neurosurg"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1177\/147323001204000213","article-title":"Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma","volume":"40","author":"Li","year":"2012","journal-title":"J Int Med Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1530\/ec-20-0414","article-title":"Presurgical somatostatin receptor ligand treatment does not affect tumor consistency in gh-secreting pituitary macroadenomas","volume":"10","author":"Araujo-Castro","year":"2021","journal-title":"Endocr Connect"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01741.x","article-title":"Preoperative lanreotide treatment for gh-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage","volume":"58","author":"Lucas","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B63","article-title":"Effects of treatment with somatostatin analogues on the occurrence of apoptosis in somatotropinomas","volume":"24","author":"Wasko","year":"2003","journal-title":"Neuro Endocrinol Lett"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/bf01411403","article-title":"Absence of apoptosis in somatotropinomas treated with octreotide","volume":"139","author":"Saitoh","year":"1997","journal-title":"Acta Neurochir (Wien)"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.11.7986","article-title":"Effects of octreotide treatment on the proliferation and apoptotic index of gh-secreting pituitary adenomas","volume":"86","author":"Losa","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-107243","article-title":"Preoperative somatostatin analogue treatment might trigger apoptosis and autophagy in tumor tissues of patients with acromegaly: A pilot study","volume":"126","author":"Dagistanli","year":"2018","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e66927","DOI":"10.1371\/journal.pone.0066927","article-title":"Attenuated rorc expression in the presence of emt progression in somatotroph adenomas following treatment with somatostatin analogs is associated with poor clinical recovery","volume":"8","author":"Lekva","year":"2013","journal-title":"PloS One"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2197","article-title":"The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response","volume":"95","author":"Fougner","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13851","article-title":"E-cadherin expression is associated with somatostatin analogue response in acromegaly","volume":"23","author":"Venegas-Moreno","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1177\/1066896912471850","article-title":"Expression and significance of E-cadherin and B-catenins in pituitary adenoma","volume":"21","author":"Zhou","year":"2013","journal-title":"Int J Surg Pathol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.646210","article-title":"Epithelial-mesenchymal transition in the resistance to somatostatin receptor ligands in acromegaly","volume":"12","author":"Gil","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10020460","article-title":"Implications of heterogeneity of epithelial-mesenchymal states in acromegaly therapeutic pharmacologic response","volume":"10","author":"Gil","year":"2022","journal-title":"Biomedicines"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3318","article-title":"Tumor shrinkage with lanreotide autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial","volume":"99","author":"Caron","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.10.6027","article-title":"Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls","volume":"84","author":"Biermasz","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1530\/eje-14-0249","article-title":"Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial","volume":"171","author":"Fougner","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-019-00952-0","article-title":"Pretreatment with somatostatin analogs does not affect the anesthesiologic management of patients with acromegaly","volume":"22","author":"Losa","year":"2019","journal-title":"Pituitary"},{"key":"B77","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s007010050316","article-title":"Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study","volume":"141","author":"Kristof","year":"1999","journal-title":"Acta Neurochir (Wien)"},{"key":"B78","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12902-017-0205-3","article-title":"Prolonged preoperative treatment of acromegaly with somatostatin analogs may improve surgical outcome in patients with invasive pituitary macroadenoma (Knosp grades 1-3): A retrospective cohort study conducted at a single center","volume":"17","author":"Duan","year":"2017","journal-title":"BMC Endocr Disord"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03669-4","article-title":"Predictors of postoperative biochemical remission in acromegaly","volume":"151","author":"Yao","year":"2021","journal-title":"J Neurooncol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"e61523","DOI":"10.1371\/journal.pone.0061523","article-title":"Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: A systematic review and meta-analysis","volume":"8","author":"Pita-Gutierrez","year":"2013","journal-title":"PloS One"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1351","article-title":"Does preoperative somatostatin analog treatment improve surgical cure rates in acromegaly? A new look at an old question","volume":"93","author":"Beckers","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B82","doi-asserted-by":"publisher","first-page":"14070","DOI":"10.1038\/s41598-019-50639-6","article-title":"Preoperative somatostatin analogues in patients with newly-diagnosed acromegaly: A systematic review and meta-analysis of comparative studies","volume":"9","author":"Yang","year":"2019","journal-title":"Sci Rep"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-018-0916-0","article-title":"Pre-surgical medical treatment, a major prognostic factor for long-term remission in acromegaly","volume":"21","author":"Albarel","year":"2018","journal-title":"Pituitary"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01873-9","article-title":"Predictors of postoperative biochemical remission in lower knosp grade growth hormone-secreting pituitary adenomas: A large single center study","volume":"46","author":"Zhang","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.5603\/EP.a2020.0050","article-title":"Therapeutic effect of presurgical treatment with longacting octreotide (Sandostatin\u00ae Lar\u00ae) in patients with acromegaly","volume":"71","author":"Bolanowski","year":"2020","journal-title":"Endokrynol Pol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2020.101354","article-title":"Efficacy and predictors of short-term first-generation somatostatin analog presurgical treatment in acromegaly: A hospital-based study of 237 cases","volume":"55","author":"Shen","year":"2020","journal-title":"Growth Horm IGF Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2015.07.019","article-title":"Cost-effectiveness analysis of preoperative treatment of acromegaly with somatostatin analogue on surgical outcome","volume":"26","author":"Margusino-Frami\u00f1\u00e1n","year":"2015","journal-title":"Eur J Intern Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-015-0242-6","article-title":"Cost-effectiveness analysis of two therapeutic schemes in the treatment of acromegaly: A retrospective study of 168 cases","volume":"38","author":"Duan","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"B89","doi-asserted-by":"publisher","first-page":"A745","DOI":"10.1016\/j.jval.2014.08.162","article-title":"Long-term cost-effectiveness of biphasic human insulin 30 in people with type 2 diabetes with inadequate glycaemic control on oral antidiabetic drugs in China","volume":"17","author":"Hua","year":"2014","journal-title":"Value Health"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-012-0384-x","article-title":"Changes in acromegaly treatment over four decades in Spain: analysis of the spanish acromegaly registry (Rea)","volume":"16","author":"Sesmilo","year":"2013","journal-title":"Pituitary"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1500763","article-title":"Clinical, hormonal and magnetic resonance imaging (Mri) predictors of transsphenoidal surgery outcome in acromegaly","volume":"150","author":"Bourdelot","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2018.06.009","article-title":"Endoscopic endonasal approach to the growth hormone-secreting pituitary adenomas: endocrinologic outcome in 68 patients","volume":"117","author":"Taghvaei","year":"2018","journal-title":"World Neurosurg"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2020.101342","article-title":"A single-center observational study assessing the predictive factors associated with the prognosis of acromegaly","volume":"55","author":"Diri","year":"2020","journal-title":"Growth Horm IGF Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00429","article-title":"The change in distance between bilateral internal carotid arteries in acromegaly and its risk factors","volume":"11","author":"Yan","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B95","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1365-2265.2011.04193.x","article-title":"Acromegaly surgery in manchester revisited\u2013the impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission","volume":"76","author":"Wang","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B96","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1530\/eje-12-0602","article-title":"Long-term outcome in patients with acromegaly: analysis of 1344 patients from the german acromegaly register","volume":"168","author":"Sch\u00f6fl","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1227\/NEU.0b013e318265a288","article-title":"Surgical and endocrinological outcomes in the treatment of growth hormone-secreting pituitary adenomas according to the shift of surgical paradigm","volume":"71","author":"Ku","year":"2012","journal-title":"Neurosurgery"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-017-0791-0","article-title":"Somatostatin receptor ligands in the treatment of acromegaly","volume":"20","author":"Gadelha","year":"2017","journal-title":"Pituitary"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1210\/er.2010-0002","article-title":"Resistance to somatostatin analogs in acromegaly","volume":"32","author":"Colao","year":"2011","journal-title":"Endocr Rev"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-012-0445-1","article-title":"Growth hormone granulation pattern and somatostatin receptor subtype 2a correlate with postoperative somatostatin receptor ligand response in acromegaly: A large single center experience","volume":"16","author":"Brzana","year":"2013","journal-title":"Pituitary"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2012.11.007","article-title":"Novel pathway for somatostatin analogs in patients with acromegaly","volume":"24","author":"Gadelha","year":"2013","journal-title":"Trends Endocrinol Metab"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa387","article-title":"Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly","volume":"105","author":"Coopmans","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-019-01020-3","article-title":"Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the primarys study","volume":"23","author":"Petersenn","year":"2020","journal-title":"Pituitary"},{"key":"B104","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.clineuro.2018.02.006","article-title":"Presurgical treatment with somatostatin analogues in growth hormone-secreting pituitary adenomas: A long-term single-center experience","volume":"167","author":"Lv","year":"2018","journal-title":"Clin Neurol Neurosurg"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1080\/01616412.2017.1296653","article-title":"Efficacy of transsphenoidal surgery in achieving biochemical cure of growth hormone-secreting pituitary adenomas among patients with cavernous sinus invasion: A systematic review and meta-analysis","volume":"39","author":"Briceno","year":"2017","journal-title":"Neurol Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1530\/eje-18-0254","article-title":"Mri T2 signal intensity and tumor response in patients with gh-secreting pituitary macroadenoma: primarys post-hoc analysis","volume":"1","author":"Bonneville","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1530\/erc-16-0356","article-title":"T2-weighted mri signal predicts hormone and tumor responses to somatostatin analogs in acromegaly","volume":"23","author":"Potorac","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0766-8","article-title":"Quantitative analyses of T2-weighted mri as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly","volume":"52","author":"Heck","year":"2016","journal-title":"Endocrine"},{"key":"B109","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s11102-020-01096-2","article-title":"Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: A single center experience from a cohort of 131 patients with acromegaly","volume":"24","author":"Swanson","year":"2021","journal-title":"Pituitary"},{"key":"B110","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s11102-020-01077-5","article-title":"Radiomics model predicts granulation pattern in growth hormone-secreting pituitary adenomas","volume":"23","author":"Park","year":"2020","journal-title":"Pituitary"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-018-5876-2","article-title":"Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted mri","volume":"29","author":"Kocak","year":"2019","journal-title":"Eur Radiol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.51.227","article-title":"Somatostatin (Srif) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide","volume":"51","author":"Park","year":"2004","journal-title":"Endocr J"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1360369","article-title":"Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology","volume":"136","author":"Pl\u00f6ckinger","year":"1997","journal-title":"Eur J Endocrinol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1999.00812.x","article-title":"Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: A retrospective study","volume":"51","author":"Razzore","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2145","article-title":"Expression of sstr2a, but not of sstrs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide","volume":"98","author":"Casar-Borota","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-014-0602-9","article-title":"Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: A systematic review and meta-analysis using the grade system","volume":"18","author":"Nunes","year":"2015","journal-title":"Pituitary"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2014.04.009","article-title":"Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas. A meta-analysis","volume":"37","author":"Zhang","year":"2015","journal-title":"Brain Dev"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13427","article-title":"Molecular evidence and clinical importance of B-arrestins expression in patients with acromegaly","volume":"22","author":"Coelho","year":"2018","journal-title":"J Cell Mol Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1530\/erc-12-0020","article-title":"Aip expression in sporadic somatotropinomas is a predictor of the response to octreotide lar therapy independent of sstr2 expression","volume":"19","author":"Kasuki","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac610","article-title":"Survivin: A potential marker of resistance to somatostatin receptor ligands","volume":"108","author":"Herkenhoff","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-021-01163-2","article-title":"Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results","volume":"24","author":"Labadzhyan","year":"2021","journal-title":"Pituitary"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.04.009","article-title":"Oral octreotide: A review of recent clinical trials and practical recommendations for its use in the treatment of patients with acromegaly","volume":"28","author":"Yuen","year":"2022","journal-title":"Endocr Pract"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1636047\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T05:24:48Z","timestamp":1767331488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1636047\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":122,"alternative-id":["10.3389\/fendo.2025.1636047"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1636047","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"article-number":"1636047"}}